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A 69-year-old male was diagnosed in February 2004 with
stage IV extranodal marginal zone B cell lymphoma involving
the mediastinal nodes, lung parenchyma and bone marrow
with high LDH. Shortness of breath developed following the
5th course of Rituximab-CHOP chemotherapy (cyclophospha-
mide, Vincristine, Doxorubicin, Prednisolone). Bronchoscopy
guided transbronchial lung biopsy revealed interstitial
thickening and type II pneumocyte activation, compatible with
interstitial pneumonitis. After treatment with prednisolone a
complete resolution of the dyspnea was observed. The patient
was well on routine follow-up at the outpatient clinic, with
no progression of lymphoma or interstitial pneumonitis.
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INTRODUCTION
Rituximab, a chimeric anti-CD20 IgG1 mono-
clonal antibody, is an effective treatment for B-cell
low grade lymphomas. This includes extranodal
marginal zone B cell lymphoma,
1-3 diffuse large
B-cell lymphoma,
4 refractory idiopathic thrombo-
cytopenic purpura,
5 and other autoimmune
disorders.
6
The proposed mechanism of action for this
depletion includes antibody-dependent cell-me-
diated cytotoxicity, complement-dependent cyto-
toxicity, and direct induction of apoptosis.
7
Interstitial pneumonitis and bronchiolitis
obliterans with organizing pneumonia
8-10 have
been recently reported when using rituximab
alone or in combination with other medications.
We report a case of interstitial pneumonitis in
a patient with disseminated extranodal marginal
zone B cell lymphoma after the 5th cycle of
rituximab and CHOP.
CASE REPORT
A 69-year-old male was diagnosed in February
2004 with stage IV extranodal marginal zone B
cell lymphoma involving the mediastinal nodes,
lung parenchyma and bone marrow.
Past medical history included one vessel disease,
for which the patient underwent percutaneous
coronary angioplasty; diabetes mellitus, and
hypercholesterolemia. Medications included glim-
epiride, aspirin, isosorbide dinitrate, nicoradil, and
atorvastatin. None of these drugs had been taken
since the diagnosis of non-Hodgkin’s lymphoma.
Following the 5th course of rituximab-CHOP
chemotherapy the patient was admitted with
neutropenic fever accompanied by generalized
weakness and mucositis.
Empiric broad spectrum antibiotics were started
along with granulocyte-colony stimulating factor.
Despite recovery of the neutrophil count, the
shortness of breath was aggravated and arterial
blood gas analysis revealed hypoxemia (PaO2 =
55).
Gram stain and special stains of the sputum for
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acid-fast bacilli, pneumocystis carinii, and fungi
were negative. Routine cultures for bacteria, fungi
and mycobacteria yielded no growth. A chest
X-ray showed progressive infiltrates in both lung
fields. A computed tomography (CT) scan of the
lung revealed bilateral patchy ground-glass
opacities, suggestive of new onset interstitial
pneumonitis. CT also showed a reduced primary
mass in the right middle lobe, consistent with the
initial primary lesion (Fig. 1).
Extrathoracic echocardiogram showed normal
left ventricular contractility with unaltered ejection
fraction. Cardiac enzymes were also normal.
Ventilation perfusion scan showed no evidence of
pulmonary artery embolism. Fiberoptic bronchos-
copy revealed no evidence of endobronchial
lesion. No malignant cells were found in the
bronchoalveolar lavage fluid.
Gram stains, special analysis and cell cultures
obtained from BAL and sputum following
fiberoptic bronchoscopy were negative for bacteria,
acid-fast bacilli, fungi and pneumocystis carinii.
Bronchoscopy guided transbronchial lung biopsy
was performed, showing interstitial thickening
and type II pneumocyte activation compatible
with interstitial pneumonitis (Fig. 2).
The patient was treated with prednisolone, 1
mg/kg a day, for 2 weeks. The dyspnea and
tachypnea gradually improved, in addition to
blood oxygenation and chest X-ray. A subsequent
CT scan following prednisolone treatment showed
marked improvement of the multifocal patchy
interstitial infiltration and ground glass opacities;
as well as a reduction in the primary lymphoma
lesion.
After 42 days of hospitalization, the patient was
discharged on a tapering prednisolone regimen.
He experienced complete resolution of dyspnea
and dyspnea on exertion. He was well on routine
follow-up at the outpatient clinic, with no
lymphoma progression or interstitial pneumonitis.
DISCUSSION
The optimal therapeutic management for patients
with non-gastric extranodal marginal zone B cell
lymphoma has not yet been defined. For localized
disease, local treatment (either radiotherapy or
surgery) will typically achieve excellent disease
control.
11-13 When the disease is advanced or dis-
seminated, several chemotherapeutic agents alone
in combination are usually administered. These
regimens include alkylating agents, anthracyclins,
steroids, and purine analogs.
2,3,13 Anthracylines-
based chemotherapy is typically recommended in
patients with histological transformation or with
high tumor mass (i.e. high LDH or a mass greater
than 7 cm).
13
The use of rituximab alone or combination with
cytotoxic chemotherapeutic agents is a new treat-
ment breakthrough in disseminated or refractory
disease. This is because extranodal marginal zone
B cells typically express the CD20 antigen.
13,14
Adverse pulmonary reactions to rituximab
occur as reversible events during the first infusion
in 38% of patients. In addition, severe human
Fig. 1. Computed tomography of the chest, showing new
bilateral patchy ground-glass opacities.
Fig. 2. Transbronchial lung biopsy, showing interstitial
thickening and type II pneumocyte activation (× 200,
hematoxylin and eosin).Rituximab-CHOP Induced ILD in EMZBCL
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antibody infusion reactions, generally occurring
during the first 2 hours of the first infusion, can
present with hypotension or angioedema. Pulmo-
nary involvement manifests in the form of
bronchospasm, hypoxia, infiltrates and even acute
respiratory distress syndrome.
15 Late occurring
pulmonary toxicities after the administration of
rituximab have rarely been reported.
8-10,15-18
Mechanisms leading to rituximab-induced inter-
stitial lung disease are not yet completely
elucidated. However, dysregulated cellular cytoto-
xicity may be related to a mechanism of delayed
pulmonary toxicity.
17,19 Cytotoxic T lymphocytes
(CTL) are believed to play an important role in
long term anti-tumor effects after rituximab
treatment.
17,19 Their activation (‘cross-priming’)
appears to be induced by dendritic cells, which
mature under the influence of cell-derived
peptides resulting from rituximab-induced tumor
destruction.
17,19 CTL activation may produce
vascular and alveolar damage. Disturbed cellular
cytotoxicity can also result from the interaction of
rituximab with CD 20+ T-cells,
17,20-22 or by cross-
reactivity between lung and tumoral antigens
with possible generation of a self reactive clone
17
Pulmonary leukostasis is associated with
activation of the complement system and changes
in endothelial adhesivity induced by elevated
cytokine levels. This leukostasis may also con-
tribute to the dyspnea and bronchospasm often
encountered in patients with high tumor burden
after treatment with rituximab.
17,23,24
The emergence of pulmonary infiltrates in
patients treated with rituximab and CHOP
chemotherapy remains a difficult diagnostic
problem. Many differential diagnoses need to be
considered, including lymphoma progression,
infection, cardiogenic edema, radiation pneumonitis,
pulmonary hemorrhage, and allergies.
One of the major clinical challenges in these
patients is ruling out opportunistic infection or
lymphoma progression. The infectious etiologies
of diffuse interstitial infiltrates in the lungs are
multiple.
25 They include any Gram-negative or
Gram-positive agents, fungi (Aspergillus, Candida),
parasites (Pneumocystis carinii, Toxoplasma gondii),
or viruses (Herpes simplex, Varicella zoster,
Cytomegalovirus).
25
Non-invasive tests and studies such as chest
X-ray, CT scan, echocardiogram, pulmonary
function tests, and arterial blood gas analysis can
easily determine the pattern of pulmonary disease
present. However, fiberoptic bronchoscopy with
bronchoalveolar lavage and lung biopsy is usually
necessary to eliminate infection or lymphoma
progression. The exclusion of all known etiologic
factors associated with pulmonary interstitial
infiltrates is essential for diagnosing rituximab-
induced interstitial pneumonitis.
We conclude that physicians should be aware of
this rare, but possible complication of interstitial
pneumonitis after combination rituximab-CHOP
chemotherapy.
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